CHINA
Regulatory Authority Overview
Last Content Review/Update: December 20, 2024
Important Dates:
All drug clinical trials conducted after March 31, 2026, are required to follow the ICH Harmonised Guideline for Good Clinical Practice E6(R3).
Regulatory Framework in China
National Medical Products Administration (NMPA)
The NMPA, previously the State Drug Administration, is the main regulatory body overseeing clinical research in China.
The NMPA’s roles include:
National drug registration management.
Regulation of clinical trials.
Evaluation of drug clinical trial applications, marketing authorization applications, supplementary applications, and overseas drug production registration applications.
Key Responsibilities:
Organizing the examination and approval of clinical trials according to various regulations such as the Drug Administration Law (DAL), the Drug Registration Regulation (DRR), and more.
Implementing guidelines and policies for drug safety, quality management, risk management, and international cooperation.
Clinical Trial Application Process
The applicant must register their drugs according to categories, which determines the review process.
Categories of Drug Registration:
Chinese Medicines: Traditional medications.
Chemical Medicines: Standard pharmaceuticals.
Biological Products: Includes vaccines and gene therapies.
Drug classification types include:
Innovative drugs not previously marketed (clear structures and effects).
Modified new drugs improving dosage/forms.
Imitation drugs consistent with marketed reference products.
Generic drugs that have been marketed elsewhere.
Drugs under application for marketing in China, already marketed abroad.
Evaluation Phases:
Review phases range from Phase I to Phase IV and include bioequivalence studies.
Ethics committee (EC) review is required before drug trials begin, with the possibility for concurrent processing with NMPA approval.
NMPA's Framework for Drug Evaluation and Ethics Review
The DRR stipulates the necessity of submission of several critical documents including:
Risk management plans.
Evidence of the prior efficacy and safety of the drug from completed trials.
Ethical review from the appropriate ethics board, which must not start until NMPA gives approval.
Safety and Risk Management
NMPA emphasizes a risk-based approach to all aspects of drug registration, prioritizing transparency, fairness, and justice.
Safety monitoring encompasses adverse effect reporting and pharmacovigilance.
National Health Commission (NHC)
The NHC is tasked with overseeing human genetic resources management in China post SC-Order777 effective May 1, 2024.
Responsibilities include:
Coordinating health policies regarding genetic resources and ethical compliance in scientific research involving HGR.
Ensuring the ethical use and management of human genetic materials, requiring informed consent for collection and usage.
Clinical Trials and Ethics Committees (EC)
Overview of Clinical Trials
NMPA’s GCP guidelines emphasize that clinical trials should only commence with prior NMPA and EC approvals.
Institutions are required to establish ethics committees to ensure ethical standards in biomedical research are met, adhering to international guidelines such as the Declaration of Helsinki.
Ethical Review Process
Each clinical institution must have an EC responsible for:
Approving clinical trial protocols.
Ensuring participant rights, welfare, and informed consent procedures are maintained.
EC Composition and Functions
ECs must consist of members with a range of qualifications to ensure comprehensive ethical evaluation:
Members should include professionals from medical, legal, ethical, and public health sectors.
They must operate independently and objectively in their review processes to protect the participants' rights and welfare.
Participant Rights and Informed Consent
Participants must be fully informed about the study and give voluntary consent without coercion.
Informed consent forms (ICFs) must be clearly stated, avoid legal waiver language, and be reviewed and approved by ECs.
Vulnerable Populations in Clinical Trials
Extra protections are needed for vulnerable populations, which include:
Minors, pregnant women, prisoners, those with mental disability.
Special consideration is given to ensure these groups can give informed consent, normally requiring consent from a guardian as well.
Safety Reporting in Clinical Trials
Adverse Event (AE): Any untoward medical occurrence in clinical trials.
Serious Adverse Event (SAE): Events that result in significant outcomes like death or persistent disabilities.
Every AE and SAE must be reported and managed per established NMPA and EC guidelines.
Quality Management and Risk Assessment
Quality Management Systems (QMS)
Sponsors must establish quality assurance and control measures to guarantee the integrity and reliability of trial data.
Compliance with regulatory standards such as good manufacturing practices (GMP) is crucial.
Regulatory Fees and Submission Guidelines
Specific fees are charged for the drug registration process, including:
New drugs made in China: ¥192,000
New drugs made outside China: ¥376,000
Generic drugs made in China: ¥318,000
Generic drugs made outside China: ¥502,000
Submission content must include all relevant pharmaceutical details and comply with electronic documentation requirements.
Conclusion
The framework set by the NMPA and NHC defines the comprehensive regulatory environment for drug trials and human genetic resources in China, focusing on ethical conduct, participant rights protection, and stringent quality measures throughout the clinical trial lifecycle.
Submission content must include all relevant pharmaceutical details and comply with electronic documentation requirements.